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Abstract: The major determinants of drug or, al bioavailability are absorption and metabolism in
the digestive tract. Genetic variations can cause significant differences in transporter and enzyme
protein expression and function. The racial distribution of selected efflux transporter (i.e., Pgp,
BCRP, MRP2) and metabolism enzyme (i.e., UGT1A1, UGT1A8) single nucleotide polymorphisms
(SNPs) that are highly expressed in the digestive tract are reviewed in this paper with emphasis on
the allele frequency and the impact on drug absorption, metabolism, and in vivo drug exposure.
Additionally, preclinical and clinical models used to study the impact of transporter/enzyme SNPs
on protein expression and function are also reviewed. The results showed that allele frequency of the
major drug efflux transporters and the major intestinal metabolic enzymes are highly different in
different races, leading to different drug disposition and exposure. The conclusion is that genetic
polymorphism is frequently observed in different races and the related protein expression and drug
absorption/metabolism function and drug in vivo exposure can be significantly affected, resulting
in variations in drug response. Basic research on race-dependent drug absorption/metabolism is
expected, and FDA regulations of drug dosing adjustment based on racial disparity are suggested.
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1. Introduction
The gastrointestinal (GI) tract and liver are two major organs of the digestive system.
Generally speaking, digesting food ingested from the mouth and absorbing nutrition to
support the body are the major functions of the GI tract and the liver. Additionally, the GI
tract and the liver can metabolize exogenous toxins and dispose wastes and metabolites to
protect the body. For drugs administered through the oral route, which is a preferred route
due to many advantages (e.g., safety, patient compliance, ease of ingestion, pain avoidance),
the drug molecules must pass through the GI tract and the liver before reaching the systemic
circulation and then disease site. In this case, the intestine and liver could be a barrier
for drugs because the molecules can be pumped back to the intestinal lumen unchanged
or after being metabolized, followed by elimination through feces. This results in low
absorption, extensive metabolism, and poor oral bioavailability, which consequentially
influence therapeutic efficacy and/or drug safety. Drug absorption and metabolism in the
GI tract and the liver are important issues in drug development and in clinical application.
Drug disposition in the GI tract and the liver is affected by many factors, especially
metabolic enzymes and drug related transporters. It is well known that metabolic enzymes
such as cytochromes P450 (CYPs), UDP-glucuronosyltransferases (UGTs), and sulfotransferases (SULTs) are highly expressed in the liver, catalyzing the metabolism of many
drugs [1]. In addition, over recent decades, our knowledge on drug metabolism in the
intestine has been significantly expanded, and it turns out that the intestine can also participate in metabolizing many xenobiotics due to highly expressed enzymes such as UGTs
and SULTs [2]. Other than metabolic enzymes, drug related uptake and efflux transporters
such as P-glycoprotein (Pgp), Breast Cancer Resistance Protein (BCRP), and multidrug
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resistance-associated protein 2 (MRP2) are also highly expressed in these two organs, which
can pump drug molecules and/or their metabolites in or out the body [3,4]. The functions of these enzymes and transporters dominate many drugs’ absorption, distribution,
metabolism, and excretion (ADME) and their in vivo exposure [5]. Basic research showed
that the expression levels of these enzymes and transporters including the prevalence of
their genetic polymorphisms can be highly different in different races at both physiological
and pathological conditions [6,7]. The racial differences in drug disposition in the GI tract
and the liver can be clinically significant and are worthy of further assessments.
Racial disparity in drug disposition may lead to significant variability in drug exposure variability in different races. For example, it was reported that CYP3A4 activity in
Caucasians was different from that in South Asians, resulting in a difference in plasma
exposure (AUC) of midazolam when the drug was administered at the same dose [8]. Another example showed that due to higher glucuronidation rates, the clearance of morphine
in African-American children was significantly higher than that in Caucasian children,
so dose adjustments for morphine was suggested for perioperative patients of different
races [9]. Variation of drug related transporters in different races can also affect drug
in vivo exposure. For example, it was reported that the systemic exposure of rifampicin
was lower in African-Americans when compared to White and Asian populations due to
higher frequency of polymorphisms in the SLCO1B1 gene (encoding uptake transporter
OATP1B1) [10]. Since interracial variability in PK and in vivo exposure have been observed, which may lead to differences in efficacy and/or toxicity, racially dependent dosing
regimens should be recommended to ensure safe and effective use of the drug in specific
subpopulations.
Racial disparity in drug disposition and response has been realized, and racial contributions to drug efficacy and safety is an important consideration in drug development.
Regulations and guidance regarding racial disparity have been issued or recommended to
ensure enrollment of different demographic subgroups in clinical trials [11]. Additionally,
race-dependent dosing regimens have been considered and described in the labeling of
United States Food and Drug Administration (FDA)-approved drug products as reviewed
previously [12]. For example, in the label of tacrolimus, an immunosuppressive drug that
prevents rejection after organ transplant, a higher dose in African-American patients is
recommended based on the clinical observation of increased metabolism by CYP3A5 in
this subpopulation [13]. Interracial variation of drug efficacy/toxicity is important in precision medicine, and regulations have been continuously published. The FDA recognizes
the Critical Path Initiative goal to “Continue improving risk-benefit balance of approved
drugs by enhancing drug product label language to include pharmacogenetics, where
appropriate” [14].
This paper focused on factors that affect drug disposition in the GI tract and liver in
different races including interracial variations of metabolic enzymes, transporters, and
microflora. In addition, pre-clinical models used to study racial disparity are also discussed.
Drug response in different races has been frequently discussed in the literature; however,
this was not our focus in this paper since drug response is affected by many factors other
than transporter/enzyme function in the GI tract. Many research and review papers have
been published on racial disparity in drug disposition, especially drug metabolism in the
liver mediated through CYPs. The major SNPs discussed in this paper are listed in Table 1.
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Table 1. Major transporters and metabolic enzymes single nucleotide polymorphisms (SNPs).
Gene

Protein

Allele

Nucleotide Change

Amino Acid Change

Location

RS Number

ABCB1
ABCB1
ABCB1
ABCG2
ABCC2
ABCC2
ABCC2
UGT1A1
UGT1A1
UGT1A8
UGT1A8

Pgp
Pgp
Pgp
BCRP
MRP2
MRP2
MRP2
UGT1A1
UGT1A1
UGT1A8
UGT1A8

C1236T
G2677T/A
C3435T
C421A
C–24 T
G1249A
C3972T
UGT1A1*6
UGT1A1*28
UGT1A8*2
UGT1A8*3

C1236T
G2677T/A
C3435T
C421A
C-24T
G1249A
C3972T
G211A
TA repeats
C518G
G830A

G412G
A893S/T
I1145I
Q141K
V417I
I1324I
G71R
A173G
C227Y

Exon 12
Exon 21
Exon 26
Exon 5
Promoter
Exon 10
Exon 28
Exon 1
Promoter
Exon 1
Exon 1

1128503
2032582
1045642
2231142
717620
2273697
3740066
4148323
3064744
1042597
17863762

2. Drug Absorption and Metabolism Disparity in Different Races
2.1. Racial Disparity in Drug Absorption
Absorption in the GI tract for orally administered drugs is affected by many factors,
among which mucosal permeability is the dominant one. Drug molecules transport across
GI epithelia following either passive diffusion or transporter-mediated mechanisms. Passive diffusion permeability is mainly determined by physicochemical properties of drugs.
Variation across different populations is not expected to be significant under similar environments. However, when transporters are involved, interracial variation in gut mucosal
permeability is significant because protein expression and/or activity can be evidently
different, which will alter drug in vivo exposure due to genetic polymorphism in different
populations. There are hundreds of membrane transporters in mammalian cells, among
which Pgp, MRP2, and BCRP are the major drug related efflux transporters that usually affect drug absorption and bioavailability in the GI tract [15]. We will discuss racial disparity
in these three major efflux transporters.
2.1.1. Pgp Polymorphism in Different Races
P-glycoprotein (P-gp), encoded by the ABCB1 gene and also called Multidrug Resistance Protein 1 (MDR1), is a glycosylated membrane protein containing transmembrane
domains and nucleotide-binding domains, which renders the protein as a good carrier for
transporting substrates across cell membranes. P-gp was first identified as an efflux transporter in cancer cells where it was found that drugs were pumped out of the cells to cause
drug resistance [16]. In the GI tract, P-gp is expressed in the apical side of epithelial cells
and participates in pumping drug molecules from blood to the intestinal lumen, resulting
in decreased intestinal absorption. Numerous hydrophobic drugs and metabolites such as
doxorubicin, etoposide, paclitaxel, SN-38, cyclosporin A, quinine, and digoxin are P-gp
substrates; therefore, their absorption in the intestines and their oral bioavailability are
highly affected by P-gp. Each year, many papers are published reporting the impact of Pgp
on drug absorption, in vivo drug exposure, drug response, and drug resistance.
So far, at least 66 MRD1 SNPs have been identified. The SNPs most widely investigated
for their clinical implications are C3435T, C1236T, and G2677A/T. The SNP in exon 26 at
position 3435 has been associated with decreased Pgp expression without amino acid
changes. The SNP in exon 21 at position 2677 represents an amino acid change of alanine
by serine or threonine (Ala893Ser/Thr), as three different nucleotides can be found at this
position (G, T, or A). The C1236T in exon 12 that encodes for the TM6 region is essential
for substrate binding. For this SNP, there are no amino acid changes. The frequencies
of these three SNPs have been investigated extensively. A typical allele frequency in
different races is shown in Figure 1. All three alleles, C1236T, G2677T, and C3435T, exhibit
the highest frequency in Asian or South Asian populations and lowest frequency among
Africans. While C1236T occurs with similar frequency between Asian and South Asian
groups, G2677T and C3435T are noticeably more common in South Asians compared to
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in vivo exposure is more complex because of the interplay between CYPs and Pgp. It
was reported that CYP3A4 expression and activity was significantly increased in MDR1
C2677T allele carriers. Increment absorption in the GI tract due to loss of efflux function
can be compensated by increased metabolism with CYP3A4 in the liver [31]. In other
words, in vivo drug exposure could be decreased even if the absorption in the intestine is
increased due to loss of Pgp function.
The impact of C1236T on Pgp expression and function has also been investigated using
typical Pgp substrates. In vitro studies using recombinant cell lines showed that C1236T
polymorphism decreases P-gp function. For example, the intracellular accumulation of
methotrexate, doxorubicin, actinomycin D, and etoposide was higher in C1236T Caco-2
cells when compared the wild type cells [32]. In vivo impact of C1236T was confirmed
by meta-analysis from multiple studies, in which it was shown that C1236T impacts drug
exposure in the plasma using cyclosporine A as the reference Pgp substrate [33]. However,
some in vitro studies showed that C1236T increases efflux function. For example, the efflux
ratio (Pba/Pab) of sunitinib, a good Pgp substrate, was 10-fold higher (13.05 ± 0.21 vs.
1.25 ± 0.09 × 10−6 cm/s) in C1236T Caco-2 cells when compared to the wild type. One
explanation for these inconsistent results is that different compounds at different concentrations were used as the Pgp substrate in these studies.
With respect to racial disparity in drug disposition in the GI tract, South Asian populations were found to have high allele frequency (0.61, 0.65, 0.61) for C3435, C2677T,
and C1236T, respectively, while Africans had lower frequency (0.22, 0.12, 0.21) for C3435,
C2677T, and C1236T, respectively (Figure 1). Therefore, the expression and/or function
of Pgp in South Asian populations are expected to be very different from characteristics
observed in other populations.
2.1.2. Breast Cancer Resistance Protein (BCRP) Polymorphism in Different Races
BCRP, encoded by the ABCG2 gene, was initially identified from a multidrug resistant
breast cancer cell line that confers resistance to chemotherapeutic drugs. Then BCRP
protein contains six transmembrane domains and functions as a homodimer or homotetramer in transporting drugs out of the cells. Substrates of BCRP include a wide range
of chemotherapeutic drugs such as mitoxantrone, camptothecin derivates, flavopiridol,
and methotrexate, imatinib, gefitinib, vinblastine, cisplatin, and paclitaxel. Other than
drug molecules, BCRP also transports conjugates of certain organic anions, particularly
sulfated and glucuronide conjugates such as estrone-3-sulfate, SN-38-sulfate, resveratrolglucuronides, genistein-glucuronide, etc. BCRP is highly expressed in the GI tract, thus
affecting intestinal drug absorption. The highest BCRP expression level in the GI tract is
detected in the duodenum, with gradually decreasing expression from the upper to lower
parts of the intestine [34].
More than 80 naturally occurring SNPs of the ABCG2 gene in humans have been
identified, among which SNP C421A, C376T, C623T, and G1322A have been studied
extensively. C421A is the most well-studied SNP related to drug disposition in the GI tract.
This SNP exhibits the highest frequency in Asian populations, and is more common in
Latin Americans with mostly European and Native American Ancestry (LA2) than in Latin
Americans with Afro-Caribbean ancestry (LA1). In addition, the frequency of the G34A
allele is noticeably higher in South Asians than in non-Asian populations (ie., Europeans,
Africans, and Latin Americans). In contrast, C421T occurs with a similar frequency among
South Asians, Europeans, Africans, and LA1 (Figure 2).
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in C24T carriers compared to wild types in Caucasian and Chinese individuals [48,49].
Furthermore, the steady state plasma concentration of tenofovir in HIV (human immunodeficiency virus) patients was significantly higher in C24T patients compared to wild
type patients (113 ± 47 versus 93 ± 44 ng/mL, p = 0.018) [47]. Higher SN-38 plasma AUC
was also observed in cancer patients [50]. The plasma AUC of 9-nitrocamptothecin and its
9-aminocamptothecin metabolite was not changed in C24T allele carriers [51]. However,
it was reported that these two compounds are substrates of Pgp and are not specific substrates of MRP2 [52]. Since Pgp is also involved in the disposition, the above-mentioned
conclusion needs to be examined further.
Contrary to other mutations, G1249A SNP is associated with increased MRP2 protein
expression and increased efflux function. In in vitro studies, MRP2 protein expression
was increased and intracellular accumulation of multiple MRP2 substrates (e.g., sorafenib,
doxorubicin, and paclitaxel) [46,53,54] were decreased using HEK293 and LLC-PK1 cell
lines. Consistent with the results from in vitro studies, PK studies showed that the G1249A
SNP caused higher intestinal transporter activity, as evidenced by lower oral bioavailability
(~20%) and by increased clearance of talinolol when given by i.v. route in German healthy
volunteers [55].
Some in vivo studies showed inconsistent results. For instance, a clinical study showed
that the absorption rate of mycophenolic acid was about 1.5-fold (C max/AUC, 56% vs. 37%)
higher when compared to 1249G carriers [56]. Similar results were found for atorvastatin
and cyclosporine in Korean subjects, in which Cmax and AUC of atorvastatin and cyclosporine were significantly higher in 1249A carriers compared to the parameters in
1249G carriers [57,58]. However, the conclusions of these studies need further examination
because the patient number was relatively small (n = 30). Another issue is transporter
specificity. It is well-known that other than MRP2, cyclosporine is also a good substrate
of Pgp. Therefore, the PK profile may not be altered significantly, even if the function of
MRP2 is affected.
Although ABCC2 C3972T is also frequently studied, many reports are on drug response resistance, or drug related adverse reactions. Although these effects may be associated with drug absorption and bioavailability, there has been very few direct in vitro
or in vivo studies on the impact of ABCC2 C3972T SNP on MRP2 protein expression and
function.
With respect to racial disparity in drug disposition in the GI tract, the frequency of
these alleles is relatively lower compared to the other two transporters. Therefore, the
extent of interracial variations in MRP2 efflux is expected to be less than that of Pgp and
BCRP. The C-24T frequency in these populations is very similar, so there is less chance for
interracial variation due to MRP2 efflux. In terms of G1249A, which causes high efflux
function, South Asian populations have a higher frequency and therefore are expected to
have a higher MRP2 efflux in the GI tract.
2.1.4. Genetic Single Nucleotide Polymorphisms (SNPs) and Transport Functions
Many studies have been conducted attempting to correlate the impact of genetic
polymorphisms of transporters on drug disposition, especially on drug absorption, PK,
and bioavailability. Mathematic algorithms were also developed to predict the impact
of transporter/enzyme SNPs on drug disposition [59]. However, results from genetic
analysis sometimes does not correlate with those from functional analysis. Sometimes,
even controversial or inconsistent results have been observed with the same genetic SNP.
For example, as above-mentioned above in Section 2.1.1 (Pgp polymorphism in different
races), the C2677T SNP of MDR1 caused function loss when tested using tyrosine kinase
inhibitors including sunitinib, imatinib, nilotinib, dasatinib, and ponatinib in cell culture
models. However, when tested using digoxin, verapamil, vinblastine, or cyclosporine A,
this SNP did not cause significant function loss. The mechanism of these observations is not
entirely investigated and understood. One of the possible reasons for these inconsistences
or controversies is that gene mutation may not necessarily result in protein mutation. It has
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been reported that the number of SNPs in the human genome is 10–30 million, while the
number of protein coding genes in the human genome is only 20,000–35,000, suggesting that
genomic SNP may or may not be translated into proteins [60,61]. Another possible reason
is that different drugs were used in different studies to evaluate the function. However,
these probes may not have the same binding site on the protein. The protein structure of a
drug transporter is very complex, which usually include extracellular, intracellular and
transmembrane domains. Drug binding sites on the above-mentioned efflux transporters
are not completely understood, but different substrates may have different favorite binding
sites [62]. For example, it was reported that for the Pgp transporter, at least two binding
sites, H-site and R site, were reported and these binding sites have different favorite
substrates [63]. Thus, a single mutation may have a different impact on the efflux function
if the substrates interact with Pgp at different binding sites. More studies are expected to
reveal the relationship across genetic SNP, protein mutation, and transporter function.
2.2. Racial Disparity in First-Pass Metabolism
First-pass metabolism, also called first-pass clearance, first-pass effect, or first-pass
elimination, is a phenomenon in orally administered drugs where drug molecules are metabolized in the liver or in the intestine before reaching the systemic circulation. The impact
of first-pass metabolism on in vivo drug exposure and PK (pharmacokinetics) profiles can
be extremely pronounced for orally administered drugs if the drug is a robust substrate of
enzymes expressed in the intestine (e.g., UGTs) or in the liver (e.g., CYPs). Many drugs
(e.g., 5-fluorouracil, morphine, lorcainide) undergo extensive first-pass metabolism after
oral administration [64]. A considerable portion of the drug will be metabolized before
entering the blood circulation, and systemic bioavailability is dramatically decreased. The
extent of first-pass metabolism in the liver and in the intestine depends on many factors,
especially enzyme and transporter expression and activities in the intestine and in the
liver. Preclinical and clinical studies have demonstrated that drugs undergoing first-pass
metabolism usually have significant interindividual variation in oral bioavailability; therefore, racial disparity in first-pass metabolism should be taken into consideration in clinics
because enzyme and transporter expressions could be very different in different races.
2.2.1. Racial Disparity in Cytochrome P450 (CYP) Reactions
Drug metabolism is usually divided into two phases: phase I and II metabolism.
Phase I metabolism involves biotransformation such as oxidation, reduction, and hydrolysis catalyzed by different enzymes (e.g., CYPs, ADH, DPD, ALDH). Usually Phase I
metabolism increases polarity and water solubility, resulting in either direct elimination
through urine and feces or conjugation with other small molecules (e.g., glucuronic acid)
prior to elimination. Among the phase I enzymes, cytochrome P450 is the major class
including at least 57 functional genes divided into 18 families and 44 subfamilies [65].
CYPs are primarily expressed in hepatocytes involved in the formation or metabolism and
breakdown of various endogenous (e.g., cholesterol, fatty acids, lipids) and exogenous
(e.g., drugs, dietary components) compounds [66]. It is believed that CYPs are one of the
major factors that influence drug in vivo exposure, pharmacokinetics, and drug response.
Aside from the liver, CYPs are also distributed in the GI tract [67]. It is reported that among
the CYPs isoforms, CYP1A2, 2C8, 2C9, 2C19, 2D6, 3A4, and 3A5 metabolize approximately
90% of current approved drugs (14). Relative and absolute quantitative studies showed
that these CYPs isoforms represent approximately 85% of the CYPs in the liver [68].
Genetic variation in CYP genes has been studied in recent decades, with tremendous
progress made in human genomic research. Pharmacogenetics, a research area that aims
to establish how genetic variation can affect drug disposition and response, has drawn
increased attention [69]. SNPs in the CYP gene loci vary among racial groups. These
variations can influence the composition of transcribed proteins, leading to variations
in gene expression, translation of mRNA, and even activity. It is reported that function
loss polymorphisms in CYP genes usually affect splicing and expression rather than tran-
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scription or protein structures [70]. The most prevalent alleles of the above CYP isoforms
and their clinical impact in different races have been thoroughly reviewed [14,71–75]. The
investigations showed that different populations may have allele frequencies that differ
greatly from one to another. For example, the frequency of CYP2D6*4 in Asians is 0.4%, as
opposed to 28.6% in Caucasians (71-fold). The frequency of CYP2D6*10 is 70% in Asians,
and only 6.1% in Caucasians (11-fold). The prevalence of CYP3A5*3 in African-Americans,
Caucasians, Asians, and Hispanics is approximately 32%, 93%, 73%, and 65%, respectively.
Allele variations cause huge differences in activity in different populations.
Genetic variations can either increase or decrease CYP activity and lead to four types
of CYPs including poor metabolizer, intermediate metabolizer, extensive metabolizer,
and ultra-rapid metabolizer. Poor metabolizers are homozygous for a variant allele that
causes a complete loss of enzyme activity; intermediate metabolizers are heterozygous
for a reference allele and a null allele; extensive metabolizers have two active reference
alleles; and ultra-rapid metabolizers possess multiple copies of CYP genes. Different
levels of metabolizer types have been reported frequently in clinical studies. For example,
African-Americans possessing variant CYP3A4*1B alleles (heterozygotes A/G) have about
30% lower midazolam metabolism and lower systemic clearance when compared to GG
homozygotes [76]. Another example showed that the efavirenz plasma levels in AfricanAmerican subjects with the CYP2B6 homozygous 516T/T genotype (reduced function of
CYP2B6*6) are approximately 3-fold higher than individuals carrying the homozygous
G/G genotype, because of slower metabolism [77].
These phenotypic disparities in CYPs could lead to different drug responses because the clearance and in vivo drug exposure can be significantly different, as abovementioned. Therefore, it is recommended that dosing regimens require adjustments in
certain populations. For example, lipid controlling agents atorvastatin, simvastatin, and
lovastatin are good substrates of CYP3A4/5. The recommended daily doses of these agents
are 40% greater for intermediate metabolizers (CYP3A5 nonexpressers combined with
CYP3A4*1/*1 or CYP3A5 expressers combined with at least one CYP3A4*22 allele) than
the doses for poor metabolizers (CYP3A4*1/*22 and CYP3A5 nonexpressers). Similarly,
the recommended daily doses for extensive metabolizers (CYP3A4*1/*1 and at least one
functional CYP3A5*1 allele) are double the doses for poor metabolizers [78]. Another
well-known example is warfarin, an approved anticoagulant commonly used for the treatment of blood clots such as deep vein thrombosis and for the prevention of stroke in
high risk people. Application of warfarin in clinics is problematic because of its narrow
therapeutic index and significant variability in patient response. Warfarin is a good substrate of CYP2C9, which shows a higher frequency of CYP2C9*2 and *3 in Caucasians
(15% and 7.8%) than in African-Americans (1% and 0.5%). These alleles showed only 12%
and 5% activity, respectively, compared to the wild type in in vitro studies [79], resulting in
higher in vivo exposure in allele carriers. Therefore, the dose of warfarin in these populations should be reconsidered based on the in vivo clearance and racial pharmacodynamic
response [80].
It is worth noting that although genetic polymorphisms of CYPs are frequently reported and are relatively easily identified, a disconnect between SNP prevalence and
metabolic activity is reported, especially among racial and ethnic groups. For example,
CYP1A1 has four common variants including *1, *2, *3, and *4, but only CYP1A1*2C has
been associated with activity changes [81].
2.2.2. Racial Disparity in UDP-Glucuronosyltransferases (UGT) Reactions
Phase II metabolism includes conjugation of drug molecules or phase 1 metabolites
with endogenous small molecules such as gluconic acid, sulfonic acid, acetic acid, and
glutathione to form conjugates with higher polarity to facilitate elimination. Among these
reactions, glucuronidation is involved in up to 75% of xenobiotic elimination processes
including most clinically used drugs [82]. It is reported that approximately one in 10 of
the top 200 prescribed drugs can be eliminated through the glucuronidation metabolic
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pathway [83]. Since 2012, drug–drug interaction through glucuronidation has been
acknowledged in FDA guidelines for industrial drug development.
Glucuronidation is catalyzed by UDP-glucuronosyltransferases (UGTs), which are a
pathway [83]. Since 2012, drug–drug interaction through glucuronidation has been acsuperfamily of membrane bound proteins expressed in the endoplasmic reticulum (ER),
knowledged in FDA guidelines for industrial drug development.
localized in the luminal side of the ER-membrane. Human UGTs have two families conGlucuronidation is catalyzed by UDP-glucuronosyltransferases (UGTs), which are a
taining at least 22 isoforms, which are mainly expressed in the intestine and liver, but also
superfamily of membrane bound proteins expressed in the endoplasmic reticulum (ER),
in other organs (e.g., the kidney) in a tissue-specific manner. For example, UGT1A8 is
localized in the luminal side of the ER-membrane. Human UGTs have two families
highly expressed in the small intestine and colon, while UGT1A9 is highly expressed in
containing at least 22 isoforms, which are mainly expressed in the intestine and liver, but
the liver [84]. Each UGT isoform has its favored substrates, but glucuronidation activity
also in other organs (e.g., the kidney) in a tissue-specific manner. For example, UGT1A8 is
can be compensated across UGT isoforms. Glucuronidation is a major metabolic function
highly expressed in the small intestine and colon, while UGT1A9 is highly expressed in
occurring in the GI tract and liver to limit the bioavailability of orally administered drugs.
the liver [84]. Each UGT isoform has its favored substrates, but glucuronidation activity
For example, raloxifene, an approved estrogen-receptor modulator for the prevention and
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exposure. In vitro studies
showed that UGT1A1*6 and *28 are associated with lower UGT1A1 expression in human liver microsomes. Furthermore, it was found in an in vitro study that glucuronidation activity in metabolizing estradiol was significantly lower (S50 , 0.383 ± 0.097 vs.
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0.941 ± 0.064 nmol/min/mg) in UGT1A1*28 carriers [90]. Another study showed that
when bisphenol A, a good substrate of UGT1A1, was incubated with human liver microsomes, the Km was significantly lower using microsomes from UGT1A1*28 carriers
(10.6 µM vs. 16.2 µM), suggesting that the binding affinity of bisphenol A with UGT1A1*28
was lower than that of wild type. In addition, the intrinsic clearance (Clint ) was lower in
UGT1A1*28 microsomes (0.32 mL/min/mg vs 1.24 mL/min/mg), suggesting the loss of
glucuronidation function with the *28 SNP [91]. Similar correlations of UGT1A1*28 SNP
with glucuronidation activity were also found for bilirubin, ethinyl estradiol, and SN-38
glucuronidation in in vitro studies using human tissue microsomes [92–94]. UGT1A1*6 is
also associated with lower protein expression and glucuronidation function. For example,
when HEK 293 cells were transfected with the UGT1A1*6 plasmid, protein expression
levels were significantly lower (~4-fold) than that of the wild type (1A1*1), resulting in
lower (~2-fold) SN-38 glucuronidation.
In vivo studies have revealed lower parent drug concentrations or lower glucuronide
levels in the plasma of UGT1A1*28 carriers. For example, it was reported that in Japanese
patients, the ratio of SN-38-glucuronide/SN-38 in UGT1A1*28 and UGT1A1*6 SNP carriers were significantly lower than in UGT1A1*1 carriers (wild type) (3.65 vs. 6.13 and
4.03 vs. 6.13, respectively), suggesting that these two SNPs decreased UGT1A1 activity
and had a significant clinical impact on SN-38 PK [95]. Similarly, other studies have
also demonstrated that GT1A1*6 and *28 carriers have a lower plasma ratio of SN-38glucuronide/SN-38 [95,96]. However, the opposite result was reported in patients treated
with raloxifene (60 mg/day for 12 months), in which the raloxifene-glucuronide plasma
level was significantly higher (558 ± 115 nM vs. 295 ± 43 nM) in *28 carriers compared to
wild type carriers. The authors hypothesized this surprising result was probably caused by
enzyme–transporter interplay [97].
For UGT1A8 SNPs, UG1A8*2 and *3, reduced protein expression was demonstrated
using transfected Sf9 cells [98]. However, the single amino acid change in UGT1A8*2
(A173G) had little impact on glucuronidation function. In contrast, UGT1A8*3 (C277Y)
is associated with a dramatic reduction of glucuronidation function, as demonstrated by
mycophenolic acid metabolism in transfected HEK-293 and Sf9 cells [98–100]. Similar
results were also found using raloxifene as the substrate either using transfected Sf9
cells [98] or using human tissue microsomes from UGT1A8*2 and *3 allele carriers [101].
In vivo studies also showed that UGT1A8*2 had limited impact on mycophenolic acid
plasma exposure [102,103].
The most extensively studied drug is arguably irinotecan, a topoisomerase 1 inhibitor
used for the treatment of different types of cancers. Irinotecan, a prodrug of SN-38, is a good
substrate of UGT1A1. Allele UGT1A1*6 is found to be associated with decreased activity,
while 1A1*28, *60, and *93 result in reduced expression. As reviewed previously, these
polymorphisms lead to decreased clearance of SN-38, the active and toxic form of irinotecan,
which can cause severe drug toxicity including neutropenia and diarrhea. Therefore,
toxicity risks among racial groups could differ greatly, so irinotecan dosing regimens are
expected to be adjusted accordingly to avoid risk of toxicity. Another well-studied drug
is mycophenolic acid, which is a good substrate of UGT1A7/8/9 and UGT2B7. Unlike
UGT1A1, some UGT1A7, 1A8, and 1A9 SNP alleles can increase in expression. For example,
UGT1A9*1c expresses UGT proteins at a higher level, which may increase glucuronidation
activity and result in increased clearance. Therefore, clearance of mycophenolic acid in
different races could be increased in the presence of relevant UGT alleles [86].
Other than drug disposition, UGT polymorphism is associated with an increased
risk of adverse drug reactions, probably due to variations in drug disposition. It was
reported that approximately 10% of the North American population is homozygous for
the UGT1A1*28 allele, and these people are at an increased risk of neutropenia with
certain drugs. Irinotecan therapy is a prime example, because the clearance of the toxic
compound is low in affected patients [104]. The UGT1A1*28 variant is also a common
cause of Gilbert Syndrome and Crigler-Najjar Syndrome due to low clearance of bilirubin,
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a waste product that arises from the destruction of aged or abnormal red blood cells [105].
UGT polymorphism is also reported to be associated with increased cancer risk because
of reduced glucuronidation and clearance of endogenous and exogenous carcinogenic
compounds [106]. In many cases, multiple UGT polymorphisms are inherited together, and
it is often difficult to identify the actual polymorphism that contributes to adverse effects
or disease risks. Although UGT polymorphism-associated drug toxicities and disease
risks are not well studied, higher risk of drug toxicity and higher disease risks in certain
races are predicted through continuous reporting of UGT expression and activity. More
attention should be devoted to the prevention of drug toxicity and related disease states in
certain races.
3. Approaches/Models on Investigating Drug Disposition Disparity
Preclinical and clinical models have been used to study disparity in drug disposition.
Each model has its own advantages and disadvantages. In vitro cell culture models, which
contain SNPs introduced by transfection, are straightforward. However, cells are absent of
biokinetics and lack blood flow, which may not reflect drug disputation in the body. On
the other hand, animal models more closely simulate the human scenario compared to cell
lines. However, the species differences of transporters and drug-metabolizing enzymes
between humans and mice [107] may limit the use of animal models for investigating drug
disposition disparity. Therefore, it may be desirable to utilize multiple models to overcome
their individual caveat.
3.1. Study Impact of SNP on Drug Absorption and Metabolism Using Cells
Transporter or metabolic enzyme SNP transfected cell lines are widely used as in vitro
models to determine the impact of SNP on protein expression and transporter or enzyme
functions. The HEK293, MDCK, Caco-2, LLC-PK1, K562, Sf9, ES-2, SKOV3, and BLL cell
lines have been used previously, most likely because these cell lines can be transfected
easily. An important consideration in the selection of cell lines is background protein levels.
For example, Caco-2 cells have a high endogenous level of efflux transporters such as Pgp,
BCRP, and MRP2, therefore, transfection with Pgp SNP might not be an ideal option due to
a high transporter background. Instead, MDCK cells are more suitable for studying Pgp
SNPs since they have minimal efflux transporter expression. On the other hand, Caco-2
cells can be used for CYP SNP related studies, as few CYP enzymes are expressed in Caco-2
cells naturally. Another example is HEK293 cells, which have a low level of endogenous
UGT protein. HEK293 cells can be used for UGT polymorphism studies with SNP allele
transfection so that the glucuronidation function will not be affected by other isoforms.
Specific substrates, usually small molecules, are used in the above-mentioned in vitro
models to evaluate the transporter functions. For example, tyrosine kinase inhibitors such
as sunitinib, imatinib, nilotinib, dasatinib, and ponatinib have been used to investigate the
impact of Pgp polymorphism on efflux function because these drugs are robust substrates
of Pgp [108]. Since different transporters—BCRP and MRP2, for example—can share the
same substrate, substrate specificity is very important. Results can be misinterpreted if
multiple transporters are involved. In addition, since some SNPs express their protein
products at a lower level compared to the wild type, it may be necessary to normalize
intracellular drug accumulation or drug metabolism rate with the protein level to accurately
evaluate protein function. For example, ABCG2 C421A transfected cells exhibited higher
intracellular drug accumulation when compared to wild type cells in the above-mentioned
studies [35–37]. Higher intracellular accumulation usually suggests loss of efflux function.
However, when intracellular drug levels were normalized with BCRP protein levels, there
was no difference between these two types of cells, suggesting that efflux function was
normal and the difference in intracellular drug accumulation was due to different BCRP
protein expression levels [35]. Therefore, the conclusions could be inaccurate without
normalizing protein expressions.
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3.2. Study Impact of SNP on Drug Absorption and Metabolism Using Animal Models
In contrast to cell lines, animal models are extremely useful tools to understand
the impact of drug transporter and metabolizing enzyme SNPs on drug absorption and
metabolism in a whole-body system. Hereto, a number of mouse models carrying one
or more of these SNPs have been developed. For instance, a humanized transgenic
UGT1A-SNP mouse model was established almost a decade ago, which harbors the Gilbert
Syndrome-associated UGT1A variant haplotype including UGT1A1*28, UGT1A3-66T>C,
UGT1A6*2a, and UGT1A7*3 [109]. Compared to the corresponding wild type, this UGT1A
haplotype led to lower UGT1A mRNA expression and UGT1A protein synthesis. Furthermore, UGT1A transcriptional activation by dioxin, phenobarbital, and endotoxin was
significantly reduced in SNP mice. In recent years, CYP3A-humanized mice carrying the
CYP3A5 SNP, CYP3A5*3, have been established. This allele results in the almost absence
of CYP3A5 protein expression in the liver and intestine. CRISPR/Cas9 mediated editing
of the CYP3A5*3 allele allowed the creation of the CYP3A5*1 SNP mice that recapitulate the CYP3A5*1 carrier phenotype in humans [110,111]. With the development of the
genome editing technology, more animal models carrying different drug transporter or
metabolizing enzyme SNPs are anticipated. These models will undoubtedly advance our
understanding of the roles of these SNPs in drug disposition in vivo. On the other hand, it
is noteworthy that although laboratory animals share many physiological similarities with
humans, there are remarkable species differences of transporters and drug-metabolizing
enzymes between humans and mice. For example, while mice have at least six Cyp2d
(Cyp2d9, 2d 10, 2d11, 2d12, 2d13, 2d22), humans express only one functional CYP2D
enzyme, CYP2D6. The activity and substrate specificity of human and mouse CYP2D
enzymes are also diverse [112]. In addition, although UGT1A enzymes are the major
contributors to hepatic mycophenolic acid metabolism in both humans and rats, 1A9
is dominant in human and 1A1 and 1A7 are likely the principal mediators in rat [113].
The above-described humanized transgenic mice can overcome the caveats of lacking
certain enzyme/transporter in mice. However, for some enzyme/transport, their proper
functioning may require specific cellular machinery, which might also exhibit differences
between species. It is important to be aware of the species difference in drug transport and
metabolism, since it represents a major confounding factor in animal data interpretation
during drug discovery.
3.3. Study Impact of SNP on Drug Metabolism Using Microsomes
Tissue microsomes prepared from SNP allele carriers are a common in vitro model to
study the impact of SNP on metabolic enzyme functions. Usually, kinetic parameters (e.g.,
Km Vmax, Clint ) are calculated to fully evaluate substrate-enzyme binding affinity and
metabolic activity. Tissues (e.g., liver tissue, intestinal tissue) are collected from patients
carrying different SNP alleles to prepare microsomes. Specific substrates are incubated
with these microsomes to determine metabolic functions. The results help determine the
impact of SNP on the function of enzymes responsible for drug metabolism. For example,
SN-38 was incubated with liver microsomes prepared from patients with UGT1A1*6, and
*28. Metabolic rates at different SN-38 concentrations were then measured, and kinetic
parameters were calculated to determine the impact of *6 and *28 on glucuronidation [90].
3.4. Clinical Studies
In clinical studies, specific substrate drugs are usually used to determine the impact of
SNP on drug disposition. Thereafter, plasma PK profiles are determined and PK parameters
(AUC, t1/2 , clearance) are calculated. By comparing PK parameters between different SNP
carriers, the extent of disparity can be identified. For example, to examine the effects of
SNPs on Pgp function, phenytoin and 3’- p-hydroxypaclitaxel were administered to Indian
and Japanese populations. PK profiles were obtained, and the results showed that wild
type patients displayed significantly higher plasma drug exposure than MDR1 C3435T
carriers, suggesting higher oral bioavailability of these drugs due to loss of Pgp efflux
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functions [23,24]. Aside from plasma drug exposure level, the ratio of metabolite vs. parent
compound concentration can be used to evaluate metabolic enzyme function. For example,
the ratio of SN-38-glucuronide to SN-38 in plasma demonstrated loss of glucuronidation
function in patients with UGT1A1*6 and *28 SNPs [95, 96].
Although racial variations of metabolic enzymes at the genetic level have been frequently reported (Figures 1 and 2), the significance of their clinical impact across races
remains uncertain. One reason is that aside from genetic factors, non-genetic factors can
also affect the expression and function of an enzyme. For example, females express CYP3A4
2-fold more than males, which corresponds to a 50% incremental change in verapamil
metabolism [114]. Another source of uncertainty are compensatory mechanisms. Numerous investigations have shown that many drugs are metabolized by more than one isoform.
When the function of one isoform is reduced, others may compensate. This compensation
may be seen in mycophenolic acid, an immune-suppressant medication used to prevent
rejection following organ transplantation and to treat Crohn’s disease. Mycophenolic acid
is a good substrate of UGT1A7, 1A8, 1A9, and 2B7. When the expression and/or activity
of one isoform decreases, the drug can still undergo glucuronidation by other enzymes.
In vivo exposure may or may not change, depending on both genetic and non-genetic
factors. In summary, whether and how racial disparity in drug metabolism in the GI tract
and liver impacts in vivo exposure and drug response need to be carefully evaluated.
4. United States Food and Drug Administration (FDA) Oversight of Drug
Applications Regarding Race and Ethnicity
Despite wide acknowledgement about the importance of genetic variation to successful drug therapy, a lack of studies exist that sufficiently evaluate the effects of pharmacogenomics on health disparities. Poor implementation of pharmacogenomics into
clinical practice has been cited as responsible for this reality, due to concerns about its
cost-effectiveness, and even due to poor reporting about the impact of pharmacogenomics
on disparity. The United States Food and Drug Administration has placed increased emphasis on the issue of racial and ethnic disparity in drug disposition and metabolism in
recent years. The agency has adopted the strategy of addressing these disparities through
improvements in the conduct of clinical trials [115]. To that end, the FDA offers guidance
pertaining to the enrollment in and design of trials that may feature diverse populations,
in addition to the collection and handling of data from diverse groups.
4.1. Enrollment and Trial Design Recommendations
The FDA promotes the use of reasonably broad eligibility criteria to conduct clinical
trials that include participant groups that best represent the populations most likely to use
the drugs or biological products pending approval. The agency also acknowledges the
common, but often unnecessary exclusion of trial participants based on language barriers
or scheduling difficulties. Such exclusions may often result in the unintended effect of
making trials less diverse from the standpoint of participant racial and/or ethnic makeup.
The FDA recommends that upon greater understanding of pathways of metabolism and
excretion for drug approval candidates, expansion of participant eligibility criteria should
be considered for future trials. In the case of unnecessary exclusion resulting from historical
or habitual practices, the agency recommends similar expansion of eligibility criteria, citing
use of the Phase 3 clinical trials as an opportunity for inclusion of these people [116].
More inclusive trial practices are also encouraged. For instance, the FDA recommends
consideration of whether Phase 2 clinical trial exclusions may be modified or eliminated in
advance of a Phase 3 trial conduct. Exclusion criteria modification may also occur in the
conduct of trials focused on higher risk populations. In some instances, such populations
are racially or ethnically diverse.
Characterization of drug metabolism and excretion early during the clinical assessment process is encouraged to avoid unnecessary exclusion of diverse populations. In
addition, adaptive trial designs are recommended that would allow for the alteration of
trial populations while studies are in progress. The FDA also recommends the use of
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targeted inclusion of specific population groups who might possess a particular disease
severity, and for whom a drug’s effect might be more readily demonstrated. The agency
also suggests re-enrollment of early-phase clinical trial participants into later-phase trials to
assist in obtaining information about the treatment of rare conditions in certain segments
of the population [116].
4.2. Diminishment of Participation Barriers
The FDA recommends steps be taken to make enrollment processes easier for potential
participants, which includes technology-mediated methods for interfacing with participants. In addition, personal interaction including the use of mobile medical personnel may
increase enrollment in underrepresented populations. Effective advertisement of financial
reimbursements and/or incentives are also recommended to better attract underrepresented groups for study participation [116]. Use of inclusive outreach to the public in
advance of clinical trial commencement is recommended. This includes direct engagement
with communities, with emphasis on building relationships with potential participants and
community leaders and support personnel. Furthermore, post-trial engagement is encouraged to maintain rapport and trust with diverse populations [109]. Locations possessing a
higher concentration of underrepresented groups are recommended as sites for conducting
inclusive clinical trials. With respect to participant recruitment, use of health providers and
study coordinators with shared cultural backgrounds with study participants is a favored
strategy. The FDA also encourages frequent scheduling of recruitment events, even in
non-clinical locations and during cultural and social gatherings. In addition, the use of
multilingual trial brochures and support staff is encouraged to attract participants who
have communication limitations [116].
4.3. Racial and Ethnic Data Collection
The FDA sets minimum standards for collecting, maintaining, and reporting data
pertaining to racial and ethnic groups. The agency recommends the use of a two-question
format for the collection of information. The first question should pertain to ethnicity,
whereas the second question should pertain to race. Clinical trial participants are recommended to self-report ethnic and/or racial identity. Ethnic identifiers should include the
minimum options of “Hispanic or Latino” or “Not Hispanic or Latino”, accompanied by
a brief description of the terms. Racial categories are recommended to include, at minimum, identifiers and descriptions including “American Indian or Alaska Native”, “Asian”,
“Black or African-American”, “Native Hawaiian or Other Pacific Islander” or “White”.
Selection options of more than one racial designation or more subgroup designations are
encouraged [11].
The FDA recommends that the number of self-reported respondents in each racial category who choose Hispanic or Latino be reported. In addition, the number of participants
who identified only one racial category should be reported. Detailed response distributions
possessing all combinations of multiple-race identifications should also be reported, with
the minimum expectation that the number of participants identifying more than one race
be communicated [11].
5. Summary and Perspective
Racial disparity of drug disposition in the GI tract is a very important issue in drug
development and clinical practice. Genetic polymorphism of drug-related transporters and
metabolic enzymes vary substantially in different races. In vitro and in vivo studies have
demonstrated that genetic polymorphisms in transporters and enzymes cause significant
differences in protein expression and functions in SNP allele carriers, resulting in highly
variable drug absorption in the GI tract and drug metabolism in the GI tract and/or the
liver. Many studies have shown that several-fold differences in the plasma exposure of
certain drugs occur in various SNP allele carriers. These variations will eventually affect
drug response, toxicity, and resistance. Dose adjustment based on SNP mutations has
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been suggested, and toxicity risk disclosures for certain genetic alleles (e.g., UGT1A1*28)
for certain drugs (e.g., irinotecan) are required to be included on drug labels by the FDA.
However, since most of these studies are focused on SNP alleles, direct racial disparities in
drug disposition in the GI tract and the liver have not been extensively studied. Most of
the studies have been based on genetic analysis, but not racial or ethnic variants, which
is a direction upon which precision medicine may focus its future. With respect to study
models, compared to cell lines, in vivo animal models are superior in determining the
impact of genetic variation on drug disposition in the GI tract and in the liver. However,
species difference in drug deposition warrants caution in interpreting the animal data.
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